Phase 3 study

Recruiting Phase 3

Sources: ClinicalTrials.gov Checked: 14 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 3
Sponsor Merck Sharp & Dohme LLC
Registry number NCT07058077
Started 21 August 2025 Today 16 October 2026 Estimated completion 4 December 2033

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Monash Children s Hospital ( Site 1603) Clayton VIC Recruiting
Perth Children s Hospital ( Site 1601) Nedlands WA Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 14 October 2026 · not medical advice

Who can join

Age 6 Years to 17 Years
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 153

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

Inclusion criteria include, but are not limited to:

* Has possible or definite diagnosis of HeFH based on a locally accepted diagnostic algorithm or diagnosis by genetic testing results

* Has a fasted LDL-C value (evaluated by the central laboratory) that is ≥130 mg/dL

* Is receiving either:

* An optimized daily dose of statin (± nonstatin LLT)

* A nonstatin LLT with documented intolerance to at least 2 different statins, or documented intolerance to 1 statin plus refusal of statin therapy by the participant or legally acceptable representative

* Is on a stable dose of all background LLTs for at least 30 days prior to screening, with no medication or dose changes planned during participation in Part A or Part B

Exclusion Criteria:

Exclusion criteria include, but are not limited to:

* Has a history of homozygous FH based on genetic or clinical criteria, or history of known compound heterozygous FH, or double heterozygous FH

* Has a history of nephrotic syndrome

* Has any clinically significant malabsorption condition based on investigator assessment

* Was previously treated/is being treated with certain other cholesterol lowering medications, including proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors without adequate washout

Dates on the record

Started 21 August 2025
Estimated completion 4 December 2033
Registry last updated 7 October 2026
Checked by Voxsanity 14 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 7 October 2026.
  • This page last checked by Voxsanity: 14 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.